Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.

Leighl NB, Passaro A, Akamatsu H, Spira AI, Nguyen D, Qin A, Schuchard J, Gamil M, Baig M, Alexander M

DOI: 10.1080/14796694.2026.2709936
Published: 2026 Aug
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2709936,
  title = {Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.},
  author = {Leighl NB and Passaro A and Akamatsu H and Spira AI and Nguyen D and Qin A and Schuchard J and Gamil M and Baig M and Alexander M},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2709936},
  url = {https://doi.org/10.1080/14796694.2026.2709936}
}

RIS

TY  - JOUR
TI  - Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.
AU  - Leighl NB
AU  - Passaro A
AU  - Akamatsu H
AU  - Spira AI
AU  - Nguyen D
AU  - Qin A
AU  - Schuchard J
AU  - Gamil M
AU  - Baig M
AU  - Alexander M
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2709936
UR  - https://doi.org/10.1080/14796694.2026.2709936
ER  -

APA

NB, L., A, P., H, A., AI, S., D, N., A, Q., J, S., M, G., M, B., & M, A. (2026). Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2709936

Source records

pubmed · retrieved 2026-09-26T01:28:12.504Z